Tercica was founded as a biotech company with a unique focus: to develop and commercialize new products to patients with endocrine diseases. Now part of the Ipsen group, we market Increlex, Somatuline Depot, and Apokyn.

People with endocrine and neurologic diseases deserve better treatment options.

Our company is committed to fully embracing these underserved patient populations. That's why we offer distinct, novel products to help improve the lives of patients with these disorders.

We have exciting career opportunities for experienced people who share our passion for improving endocrine and neurologic health. Our company and professional relationships are guided by our vision, mission, and values.

A message to the ALS Community from Tercica. Read more »

Increlex is the world's first long-term therapy for children with short stature due to severe Primary IGFD.

Our new product for adults with acromegaly simplifies treatment with a ready-to-use, prefilled syringe.

Learn about the first and only prescription medicine that reverses offepisode motor symptoms associated with advancing Parkinson's disease.

Dysport is available in 77 countries and has been used to treat patients outside of the United States since 1991.

Dysport^tm (abobotulinumtoxinA for injection) received FDA approval in the United States on April 29, 2009 for the treatment of cervical dystonia. Its approval was based on trials with 252 cervical dystonia patients, including 2 double-blind, placebo-controlled, randomized trials, and 2 long-term, open-label extension studies.

And now, for more than 125,000 people with cervical dystonia in the United States, there's a new option in botulinum toxin type A

For important safety information, please see full Prescribing Information and Medication Guide.